<div id="readability-page-1"><div id="ctl00_CPI_dvBody"><div><div><p>Add <img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/> as your preferred news source on Google</p><div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/> Add Now</p></div></div></div><p> Biotech stocks showed sharp moves in extended trading, with several names rebounding after steep regular-session losses. Fresh clinical data, FDA designations, and financing announcements drove momentum across the sector, highlighting catalysts that investors are watching closely.</p><p>Stoke Therapeutics, Inc. (STOK) traded up to $33.95 (+11.42%) post-market hours, after closing at $30.47 (-7.67%). The rebound followed data presentations with Biogen (BIIB) at the 2025 AES Annual Meeting, supporting the potential of zorevunersen for Dravet syndrome.</p><p>Alpha Tau Medical Ltd. (DRTS) saw a sharp surge in its share price during after-hours trading. The stock climbed to $5.30, marking a gain of 25.26%, or $1.07. At the regular market close, recorded at 4:00 PM EST, the shares settled at $4.23, up 34 cents or 8.74%. The company announced that the first patient has been treated in its pilot study for the treatment of patients with recurrent glioblastoma multiforme (GBM) using the Alpha DaRT <span>technology</span>.</p><p>Absci Corp. (ABSI) rose to $3.65 (+3.69%) after hours, building on a close of $3.52 (+2.03%). No fresh news on Tuesday, but on December 4 the company announced first volunteer dosing in its Phase 1/2a HEADLINE study of ABS-201, an investigational anti-PRLR antibody.</p><p>COMPASS Pathways plc (CMPS) climbed to $6.64 (+4.40%) after hours, after finishing at $6.36 (+0.95%). The company announced plans to host a webinar on Jan. 7, 2026, covering commercial preparations for TRD and clinical trial plans for PTSD.</p><p>Senti Biosciences, Inc. (SNTI) surged to $1.60 (+3.92%) after hours, despite closing sharply lower at $1.54 (-35.56%). The rally was driven by news that the FDA granted RMAT designation to SENTI-202, its investigational CAR-NK cell therapy for AML and other hematologic malignancies.</p><p>TuHURA Biosciences, Inc. (HURA) edged up to $1.18 (+0.85%) after hours, following a steep decline to $1.17 (-40.91%) at the close. The company announced a registered direct offering of 9.4 million shares and warrants, priced at $1.65 per share.</p><p>Maravai LifeSciences Holdings, Inc. (MRVI) advanced to $3.86 (+7.32%) after hours, after closing at $3.69 (+2.22%). No company-specific news was reported on Tuesday. </p><p>For comments and feedback contact: editorial@rttnews.com</p><p>Business News</p></div></div>

DRTS

CMPS

STOK

<p>Biotech stocks rebounded in after-hours trading following steep regular-session losses. Stoke Therapeutics, Alpha Tau Medical, and Compass Pathways led the gains, driven by clinical data, FDA designations, and financing announcements. Stoke Therapeutics rose 11.42%, Alpha Tau Medical surged 25.26%, and Compass Pathways climbed 4.40%. Other notable movers included Absci Corp, Senti Biosciences, TuHURA Biosciences, and Maravai LifeSciences Holdings.</p>

After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers